|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The inclusion criteria for patients were as follows: (1) treatment-naive and treated with PEG IFN-α/RBV, (2) HCV RNA was present in serum for over 6 months before treatment, (3) negative for hepatitis B (HBV) or HIV infection and (4) lacked any other hepatic diseases.All participants in this study were Chinese Han population and infected with HCV genotype 1b and treated with subcutaneous PEG IFN-α at a dose of 180 µg once a week with the addition of 800-1000 mg/d RBV according to weight orally for 48 weeks.
|
29654010 |
2018 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).
|
29456079 |
2018 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
A one-year course of Peg-IFN has the advantage of providing immune-mediated control of the hepatitis B virus (HBV) infection, the possibility of achieving a sustained off-treatment response in nearly 30% of the patients and ultimately, HBsAg loss in approximately 30%-50% of the latter patients during long-term off treatment follow-up.
|
29427498 |
2018 |
|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression.
|
29377616 |
2018 |
|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A lower progression to cirrhosis was found in NASVAC group compared to Peg-IFN group.
|
30133478 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both physicians and patients rated melanoma recurrence much lower than even severe IFN side effects.
|
29899854 |
2018 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression.
|
29377616 |
2018 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There has been some debate if IFN-free therapy with direct-acting antivirals alters the risk for HCC.
|
29205405 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study aimed to investigate the clinical efficacy of single agent S-1 and S-1/IFN-α for HCC patients with extrahepatic metastases in a randomized, open-label, multicenter trial.
|
29377364 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study conducted a meta-analysis to evaluate the effects of adjuvant Peg-IFN-based therapy on the survival outcomes in patients with hepatitis-related HCC after the curative treatment.
|
29995763 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, after 9 months of treatment with subcutaneous injections of PEG-IFNα 2a once per week, the metastatic lung foci gradually shrunk until disappearance and the HCC lesion stabilized without progression.
|
30127887 |
2018 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IFNA1- rs1831583 and IFNA2- rs649053 are associated with the development of HCC.
|
29080269 |
2018 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, we failed to uncover any significant association between other polymorphisms in genes of IL-12 signaling pathway and HCC risk, including <i>IL18</i>-rs1946518 and -rs187238, <i>IFN-γ</i>-rs2430561, <i>IL12A</i>-rs568408, <i>IL12B</i>-rs3212227 and <i>STAT4</i>-rs7574865.
|
30310516 |
2018 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In patients with previous HCC treated with curative therapies, HCC recurrence occurred in two (25%) out of eight patients treated with IFN-based regimens and four (21%) out of 19 treated with DAA-IFN-free regimens (P = 1.0).
|
29596108 |
2018 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy.
|
28236535 |
2017 |
|
Hepatitis B
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Vitamin D serum levels and receptor genetic polymorphisms are associated with hepatitis B virus and HIV infections and IFN-λ levels.
|
29493287 |
2017 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection.
|
28983111 |
2017 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting IFNα to the liver may be a strategy to increase its efficacy locally and may increase efficacy of IFNα-based therapy of HBV infection.
|
28709686 |
2017 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Standard treatment in HBV infection includes IFN-α, nucleoside, or nucleotide analogs, which has direct antiviral activity and immune modulatory capacities.
|
28450868 |
2017 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Higher IFN-<i>λ</i>3 concentrations are associated with response to HBV vaccination, self-limited HBV infection, and HCV resolution.
|
29226133 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients who undergo surgical excision of stage III MM appear to enjoy prolonged DFS and OS when treated with TIL + IFN-<i>α</i> compared to IFN-<i>α</i> alone.
|
28913367 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IFN-α2b-treated high-risk cutaneous melanoma patients in a Phase II study.
|
29109725 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
High-dose interferon alfa-2b (IFN-α-2b) improves the survival of patients with high-risk melanoma.
|
28710916 |
2017 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that CSF-470 vaccine plus BCG plus GM-CSF can significantly prolong, with lower toxicity, the DMFS of high-risk CM pts with respect to medium-dose IFN-α2b.
|
28620382 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that restoration of IFN-stimulated genes by co-administration of the demethylating drug 5-aza-2'-deoxycitidine (decitabine [DAC]) may enhance the susceptibility to IFN-I-mediated antitumoral effects in melanoma.
|
27623509 |
2017 |